Portfolio Companies
Skinject Inc., a wholly owned subsidiary of Medicus Pharma Ltd. (NASDAQ:MDCX), is a development stage biotechnology life sciences company focused on commercializing novel treatment for non melanoma skin cancer, especially basal cell carcinoma, using a patented dissolvable doxorubicin-containing microneedle patch array (D-MNA). Watch our Skinject explainer video
>5 million
Basal Cell Carcinoma cases annually in the U.S. according to PubMed
$2 Billion
Annual Basal Cell Carcinoma Market Opportunity
Skinject US Patents granted for method of use through 2035
Skinject phase 2 clinical trial enrollment has begun
* >5million: American Cancer Society
* $2Billion: SkinJect commercial opportunity assessment by an independent 3rd party
* $2Billion: SkinJect commercial opportunity assessment by an independent 3rd party